AGS Transact (AGSTRA)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Price-to-book of 0.06, with market price ₹2.88 versus book value ₹46.57, offers a deep apparent asset discount.
• Market cap of ₹45 Cr is far below latest quarterly sales of ₹210 Cr, giving some revenue scale even after the decline.
• ROCE is still marginally positive at 1.26%, indicating at least a thin operating surplus before interest and other charges.
• Current price is closer to the 52-week low of ₹1.97, suggesting much of the bad news is openly visible to the market.

Concerns

• Latest quarter net loss of ₹194 Cr against sales of ₹210 Cr is extraordinarily weak and rapidly burning equity.
• Sales growth of -43.92% and profit growth of -1163.07% show severe business deterioration.
• Debt/Equity of 2.00 with ROCE of 1.26% and negative ROE of -21.47% leaves shareholders far behind creditors.
• Promoter holding of 26.48% is low, Piotroski F-Score is 3/9, and there is zero dividend yield.

AI Analysis

A share of AGS Transact sells for ₹2.88, but the books say shareholders own equity of ₹46.57 per share. At 0.06 times book value, this looks like Graham's asset play at first glance. But I have to ask: is the asset real, and can I wait for value to appear? The latest quarter shows sales of ₹210 Cr and a net loss of ₹194 Cr. That is nearly the entire revenue lost, and it represents a burn of roughly ₹194 Cr in three months against total equity of about ₹728 Cr. At that pace, book value is not a cushion; it is being incinerated. Sales are down 43.92% and profit growth is -1163.07%. ROE is -21.47%. ROCE is only 1.26%, so operations earn barely anything before finance costs. With debt/equity at 2.00, the lender knocks on the door before the shareholder ever sees a rupee. A Piotroski score of 3/9 tells me the financial position is weak; I won't hide behind the low P/B. Promoter holding of 26.48% is low for an Indian company, and there is no dividend. The market cap is only ₹45 Cr, so the stock has become a tiny option on survival. In Buffett's style, I prefer a wonderful business at a fair price to a poor business at a cheap price. AGS Transact is the second case. It fails my tests of predictable earning power and a durable moat. Unless the quarterly loss shrinks sharply and revenue decline stabilizes, I cannot call this a margin of safety. It may look like an asset play, and I will put it in that bucket, but only as a distressed asset play with a very short runway.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer